Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Andreeff on the Rationale for Investigating Uproleselan Plus Venetoclax and Azacitidine in AML

April 19th 2023

Michael Andreeff, MD, PhD, discusses the rationale for investigating uproleselan plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Dr Ball on Prior Research Supporting the SELECT-AML-1 Trial in Newly Diagnosed AML

April 19th 2023

Brian C. Ball, MD, discusses previous research on tamibarotene in newly diagnosed acute myeloid leukemia, and how these data support the ongoing phase 2 SELECT-AML-1 trial.

IDMC Recommends Continuation of REGAL Trial of Galinpepimut-S in AML

April 19th 2023

An independent data monitoring committee has recommended that the phase 3 REGAL trial examining galinpepimut-S in patients with acute myeloid leukemia continue as planned without modifications.

Dr Horwitz on the FDA Approval of Omidubicel in Blood Cancers Requiring Transplant

April 17th 2023

Mitchell E. Horwitz, MD, discusses the significance of omidubicel as an FDA-approved treatment option to reduce the risk of infection in patients with blood cancers and highlights key findings from the pivotal phase 3 trial.

FDA Approves Omidubicel to Reduce Infection Risk in Blood Cancers Requiring Transplant

April 17th 2023

The FDA has approved omidubicel-onlv (Omisirge) to quicken the recovery of neutrophils in the body and reduce the risk of infection in adults and pediatric patients aged 12 years and older with blood cancers who are slated to undergo umbilical cord blood transplantation after a myeloablative conditioning regimen.

Tafasitamab Plus Lenalidomide Has Continued Efficacy and Safety in R/R DLBCL

April 16th 2023

The combination of tafasitamab and lenalidomide followed by tafasitamab maintenance prolonged responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML

April 14th 2023

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

FDA Places Partial Clinical Hold on Phase 1 Trial of MT-0169 in R/R Myeloma or Non-Hodgkin Lymphoma

April 11th 2023

The FDA has placed a partial clinical hold on a phase 1 trial investigating MT-0169 in patients with relapsed/refractory multiple myeloma or non-Hodgkin lymphoma.

Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML

April 6th 2023

Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Quizartinib May Represent an Additional Therapeutic Option for FLT3-ITD+ AML

April 3rd 2023

Mark Levis, MD, PhD, discusses potential changes to the FLT3-ITD-mutated acute myeloid leukemia treatment landscape that may occur if the FDA approves quizartinib, key efficacy and safety data with the agent, and how quizartinib compares with midostaurin.

Novel CAR T Utility Must Be Confirmed Across Hematologic Malignancies

March 25th 2023

Craig Sauter, MD, discussed the common limitations of CAR T-cell therapy through timely referral and the existing questions for patients with LBCL who progress on CAR T-cell therapy.

Dr. Cortes on Defining Fitness in Patients With Hematologic Malignancies

March 24th 2023

Jorge E. Cortes, MD, discusses the importance of defining fitness in patients with hematologic malignancies prior to treatment selection.

Dr Christensen on Azacitidine Plus Venetoclax in AML

March 23rd 2023

Bradley W. Christensen, MD, discusses findings from the phase 3 VIALE-A trial in patients with acute myeloid leukemia.

Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

March 22nd 2023

Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.

Future Directions in the Management of Acute Myeloid Leukemia

March 21st 2023

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.

Emerging Treatment Strategies in Acute Myeloid Leukemia

March 21st 2023

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Eunice Wang, MD, discusses the current standards for classifying and treating unfit patients with AML, treatment considerations for patients unfit for hypomethylating agents, and the potential role of investigational menin inhibitors and immunotherapies in this population.

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Mayur Narkhede, MD, discusses the early findings for the use of siltuximab to manage cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in patients following CAR T-cell therapy and expands on the next steps for investigating this agent during the phase 2 trial.

EP0042 Wins FDA Orphan Drug Status for Acute Myeloid Leukemia

March 14th 2023

The FDA has granted an orphan drug designation to EP0042 for use as a potential therapeutic option in patients with acute myeloid leukemia with acquired resistance to FLT3 inhibitors.

Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS Lymphoma

March 14th 2023

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.